Benjamin B.'s profile picture

Benjamin B.

Vice President, Mammalian Biology and Product Management at Inscripta, Inc.

Benjamin B. has a diverse work experience in the life science industry. Benjamin currently holds the position of Vice President of Mammalian Biology and Product Management at Inscripta, Inc., starting in November 2022. Prior to this, they worked at Merck Life Science/MilliporeSigma as the Head of Portfolio Management from November 2019 to November 2022.

Before their time at Merck, Benjamin was the Product Marketing Director at Berkeley Lights, Inc. from November 2018 to November 2019. Benjamin also gained experience at Agilent Technologies, where they held multiple roles. Benjamin was the Global Manager of Strategic Market Development from December 2016 to November 2018, the Senior Product Manager for Genome Engineering and Advanced Genomics Applications from November 2015 to December 2016, and the Product Manager for Molecular and Synthetic Biology from August 2013 to November 2015.

Additionally, Benjamin co-founded Nanopore Diagnostics, LLC in December 2012 and served as its Chief Operating Officer until December 2014.

Benjamin B. has pursued higher education at Washington University in St. Louis. Although the specific start and end years are not provided, Benjamin B. has completed a Doctor of Philosophy (Ph.D.) degree in Biological and Biomedical Sciences from this institution. Additionally, they have also obtained a Master of Business Administration (MBA) degree in Business Administration and Management, General, also from Washington University in St. Louis.

Location

South San Francisco, United States

Links

Previous companies

Agilent Technologies logo

Org chart

Upgrade to view 0 reports



Offices

This person is not in any offices


I

Inscripta, Inc.

Inscripta is developing the world’s first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale.


Employees

51-200

Links